Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Shares of Hims & Hers rose 5.2% Monday after the telehealth provider ran an advertisement on Super Bowl Sunday highlighting the company's efforts to fight the obesity epidemic in America. But Heard on ...

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

For example, Brittany found that drugs being developed by Generate were modified versions of existing antibodies, and that ...